News

  1. Phase III Data Show Greater Compliance Across Demographic Groups With Agile Therapeutics' Contraceptive Patch Compared To An Oral Contraceptive
    11/1/2012

    Agile Therapeutics presented findings from a phase III pivotal trial of AG200-15, Agile's investigational once-weekly combination contraceptive patch containing ethinyl estradiol (EE) in combination with levonorgestrel (LNG).

  2. Abbott Presents Positive Results From Phase 2 "Pilot" Study Of An Interferon-Free Combination Regimen For The Treatment Of Hepatitis C
    4/19/2012

    Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced complete data from the study known as "Pilot" – Abbott's initial interferon-free study of its direct-acting antiviral agents for the treatment of hepatitis C (HCV) – showing that 91 percent of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24). 

  3. Abbott To Present Positive Phase 2 Results From Multiple Interferon-Free Studies Of Combination Regimens For The Treatment Of Hepatitis C
    4/9/2012

    Abbott (NYSE: ABT) will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress™ 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.

  4. Many Cancer Rates Continue To Decline
    4/2/2012
    Death rates from all cancers combined for men, women, and children continued to decrease in the United States between 2004 and 2008.
  5. Lilly Steps Up Efforts To Improve Diversity In Clinical Trials
    9/26/2011
    Racial and ethnic minorities are more likely to develop cancer and die from it than the general U.S. population.
  6. PAREXEL Achieves 100th Asian Ethnobridging Study Milestone
    7/25/2011
    PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that it has achieved a significant milestone by completing its 100th Asian ethnobridging study, which is designed to help biopharmaceutical companies accelerate development for the Asia/Pacific market.